PEGENZILEUKIN, Isatuximab, Isatuximab clinical trials

Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA

This study is looking at a new combination of treatments for multiple myeloma that has come back or isn't responding to current treatments. It aims to find the safest dose of these new drugs and see how well they work together to shrink the cancer or stop it from growing.